Ariad Pharmaceuticals Inc fka ARIA

[AmpleKind]

Something about the exclusion criteria for the EPIC trial that I did not realize.

It was not as stringent as we assumed. Patients with MI, and other vascular
event history, were excluded only if the event occurred in the last six months.

It seems to me that given Tasigna's more selective patient population, we may
not be much/any worse than Tasigna.

Another interesting (and obvious) point made was that the reason long term
patients on Iclusig experience have SAE's, is that they're still alive, whereas
with the other TKI's they would be already dead.

We have approved cancer drugs that extend life by a few months. Iclusig
in contast extends it by years, and for the vast majority, without SAE's.